Topical vitamin D analogs available to treat psoriasis

SKINmed

Volumn 10, Issue 6, 2012, Pages 356-360

  Oquendo, Marcial ^a   Abramovits, William ^a,b,c   Morrell, Peter ^d  

^a Dermatology Treatment and Research Center   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Dermatology Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; DRUG DERIVATIVE; VITAMIN D;

HUMAN; INTRADERMAL DRUG ADMINISTRATION; PATHOLOGY; PRACTICE GUIDELINE; PSORIASIS; REVIEW; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ADMINISTRATION, CUTANEOUS; DERMATOLOGIC AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSORIASIS; SEVERITY OF ILLNESS INDEX; UNITED STATES; VITAMIN D;

MLCS; MLOWN;

EID: 84874153078     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Grace K., Kim, DO. The rationale behind topical vitamin D analogs in the treatment of psoriasis. J Clin Aesthet Dermatol. 2010;3:46-53.
2. Murphy G, Reich K. In touch with psoriasis: topical treatments and current guidelines. J EurAcad Dermatol Venereol. 2011;25(suppl 4):3-8.
3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643-659.
4. Murphy G, Reich K. In touch with psoriasis: topical treatments and current guidelines. J EurAcad Dermatol Venereol. 2011;5(suppl 4):3-8.
5. Nagpal S, Lu J, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem. 2001;8:1661-1679.
6. Guilhou JJ. The therapeutic effects of vitamin D3 and its analogues in psoriasis. Expert Opin Investig Drugs. 1998;7:77-84.
7. Segaert S, Duvold LB. Calcipotriol cream: a review of its use in the management of psoriasis. J Dermatolog Treat. 2006;17:327-337.
8. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol. 2001;2:95-120.
9. Dam TN, Moller B, Hindkjaer J, Kragballe K. The vitamin D3 analog calcipotriol suppresses the number and antigen-presenting function of Langerhans cells in normal human skin. J Investig Dermatol Symp Proc. 1996;1:72-77.
10. Dovonex Cream [package insert]. Ballerup, Denmark: LEO Pharmaceutical; 2009.
11. Vectical ointment [package insert]. Fort Worth, TX: Galderma Laboratories; 2009.
12. Boni E. Elewski MD, William Abramovits MD, et al. A novel foam formulation of ketoconazole, 2%, for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007;6:1001-1008.
13. Duweb G, Aldebani S, Elzorghany A, Benghazil M, Alhaddar J. Calcipotriol ointment versus cream in psoriasis vulgaris. Int J Clin Pharmacol Res. 2003;23:47-51.
14. Sorilux foam [package insert]. San Antonio, TX: Stiefel Laboratories, Inc; 2011.
15. Molin L, Cutler TP, Helander I, Nyfors B, Downes N. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. BrJ Dermatol. 1997;136:89-93.
16. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol. 2002;146:351-364.
17. Berth-Jones J, Chu AC, Dodd WA, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. BrJ Dermatol. 1992;127:266-271.
18. Pinheiro N. Comparative effects of calcipotriol ointment (50 μg/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis. BrJ Clin Pract. 1997;51:16-19.
19. Veien NK, Bjerke JR, Rossman-Ringdahl I, Jakobsen HB. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. BrJ Dermatol. 1997;137:581-586.
20. Zeichner JA, Lebwohl MG, Menter A, et al. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis. 2010;86(suppl 3):5-31.
21. Calcipotriene [package insert]. Hawthorne, NY: Taro Pharmaceuticals USA; 2010.
22. Dovonex Scalp [package insert]. Ballerup, Denmark: LEO Pharmaceutical; 2010.
23. Zhu X, Wang B, Zhao G, et al. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 μg/g ointment vs. calcipotriol 50 μg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J EurAcad Dermatol Venereol. 2007; 21:466-472.
24. Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3 μg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol. 2007;6:428-435.
25. Data on file. Fort Worth, TX: Galderma Laboratories, L.P.
26. Kragballe K, van de Kerhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J EurAcad Dermatol Venereol. 2006;20:39-44.
27. Taclonex ointment [package insert]. Dublin, Ireland: LEO Pharmaceuticals; 2007.
28. Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of cal-cipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, doubleblind, controlled trial. J Am Acad Dermatol. 2008;59:455-463.
29. Zeichner JA, Lebwohl MG, Menter A, et al. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis. 2010;86(suppl 3):5-31.
30. Korver JE, Vissers WH, van Rens DW, et al. A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. Br J Dermatol. 2007;156:130-137.